Safety, pharmacokinetics and pharmacodynamics study of Leucettinib-21 in healthy subjects, Down Syndrom and Alzheimer patients

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-507075-22-00

Enrollment

140

Registered

2023-12-13

Start date

2024-01-05

Completion date

Unknown

Last updated

2026-01-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and patients with Alzheimer’s disease, A Phase 1, Double-Blind, First in Human Study to Evaluate the Safety, followed by an open single dose of Leucettinib-21 in Down Syndrome individuals, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Doses and Food Effect of Leucettinib-21 in Healthy Male Subjects, Placebo-Controlled, Randomized, Tolerability

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Countries

France

Outcome results